Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,165.11 -44.91 (-3.71%)

Streaming Delayed Price Updated: 12:39 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

July 23, 2026

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

Via The Motley Fool

Topics Lawsuit

Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks

July 23, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC? ↗

July 23, 2026

One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.

Via The Motley Fool

Topics ETFs

Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup ↗

July 23, 2026

Via Chartmill

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗

July 23, 2026

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

Via The Motley Fool

Topics ETFs

There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders ↗

July 23, 2026

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Via Investor's Business Daily

Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗

July 23, 2026

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Via The Motley Fool

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT? ↗

July 23, 2026

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Via The Motley Fool

Topics ETFs

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? ↗

July 23, 2026

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

Via The Motley Fool

Topics ETFs

Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗

July 23, 2026

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The...

Via The Motley Fool

Topics ETFs

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? ↗

July 22, 2026

IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.

Via The Motley Fool

Topics ETFs

Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗

July 22, 2026

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

Via The Motley Fool

Topics ETFs

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026? ↗

July 22, 2026

PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.

Via The Motley Fool

Topics ETFs

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. ↗

July 22, 2026

A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.

Via The Motley Fool

Topics Economy

Insider Moves Are Sending Mixed Signals Across the Tech Sector ↗

July 22, 2026

Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.

Via MarketBeat

Topics Artificial Intelligence

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors? ↗

July 22, 2026

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

Via The Motley Fool

Topics ETFs

"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗

July 21, 2026

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Via The Motley Fool

Topics Lawsuit

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? ↗

July 21, 2026

One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies.

Via The Motley Fool

Topics ETFs

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? ↗

July 21, 2026

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

Via The Motley Fool

Topics ETFs

1 Unstoppable Vanguard ETF That Could Turn $500 Per Month Into $1 Million ↗

July 21, 2026

The Vanguard Growth ETF solely focuses on America's largest growth companies.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising ↗

July 21, 2026

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.

Via Benzinga

Topics Lawsuit

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗

July 21, 2026

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

Via The Motley Fool

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

July 21, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? ↗

July 21, 2026

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Via The Motley Fool

Topics ETFs

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

July 21, 2026

Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p...

Via StockStory

Topics Stocks

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)

July 20, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? ↗

July 20, 2026

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Via The Motley Fool

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

July 20, 2026

Beam Therapeutics' growing pipeline could reward patient investors.

Via The Motley Fool

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗

July 20, 2026

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Via The Motley Fool

Topics ETFs

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗

July 20, 2026

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.